Lumea and Myriad Genetics have partnered to integrate Myriad’s Prolaris® and MyRisk® molecular diagnostic tests into Lumea’s BxLink™ digital pathology platform. LEHI, UT, UNITED STATES, February 5, 2025 /EINPresswire.com/ —…
Lumea partners with Mindpeak to integrate AI tools like Breast Suite and Gleason grading into its platform, advancing precision in digital pathology. LEHI, UT, UNITED STATES, January 28, 2025 /EINPresswire.com/…
LEHI, UT, UNITED STATES, December 5, 2024 /EINPresswire.com/ — Lumea, a leader in digital pathology solutions, is excited to announce that Cxbladder™, a suite of non-invasive genomic urine tests optimized…
Out of 150 companies recognized, Lumea secured the 33rd spot in the prestigious 2024 Top Workplace Awards LEHI, UT, UNITED STATES, October 16, 2024 – Lumea has been recognized as a Top…
Park City, UT — August 22, 2024 — Nestled at the base of the breathtaking Wasatch Mountains in picturesque Park City, Utah, the Digital Diagnostic Summit will gather the brightest…
FOR IMMEDIATE RELEASE [May 15, 2024] – Lumea Inc., a trailblazing digital pathology company dedicated to advancing tissue standardization, is thrilled to announce a standalone version of their Smart Tissue…
*BxLink has not been approved by the FDA for digital primary diagnosis. Refer to CAP guidelines regarding the use of digital pathology technologies.
